Switching P2Y12-receptor inhibitors in patients with coronary artery disease.
about
Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfallsNanotechnology in diagnosis and treatment of coronary artery disease.A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study.Role of Genetic Testing in Patients undergoing Percutaneous Coronary Intervention.Dual Antiplatelet Therapy Duration: Reconciling the Inconsistencies.Clinical pathways and management of antithrombotic therapy in patients with acute coronary syndrome (ACS): a Consensus Document from the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Cardiology (SIC), Italian Society of EA Safety Evaluation of Cangrelor in Patients Undergoing PCI.Pre-treatment with P2Y12 inhibitors in ACS patients: who, when, why, and which agent?Reviewing the controversy surrounding pre-treatment with P2Y12 inhibitors in acute coronary syndrome patients.Optimizing the Use of Cangrelor in the Real World.Ticagrelor for the treatment of atherosclerotic disease: insights from the PARTHENON clinical development program.Single or dual antiplatelet therapy after PCI.Antithrombotic therapy for patients with STEMI undergoing primary PCI.Purinergic Signalling: Therapeutic Developments.Newer P2Y12 Inhibitors: How Does the Interventional Cardiologist Choose?Contemporary use of P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction referred to primary percutaneous coronary interventions in Poland: Data from ORPKI national registry.The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shifts.In-stent thrombosis when switching ticagrelor to clopidogrel after percutaneous coronary intervention.Antiplatelet Therapy Changes for Patients With Myocardial Infarction With Recurrent Ischemic Events: Insights Into Contemporary Practice From the TRANSLATE-ACS (Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns anCombination antiplatelet treatment in coronary artery disease patients: A necessary evil or an overzealous practice?Antiplatelet Therapy for Non-ST-Segment Elevation Myocardial Infarction in Complex "Real" Clinical Scenarios: A Consensus Document of the "Campania NSTEMI Study Group".Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention.Lipid rafts are essential for release of phosphatidylserine-exposing extracellular vesicles from platelets.Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery DiseaseDe-Escalation of P2Y12 Receptor Inhibitor Therapy after Acute Coronary Syndromes in Patients Undergoing Percutaneous Coronary Intervention
P2860
Q26775125-AE8DC85A-B159-4C65-A257-094AC59C9201Q30362371-DAE4BF3C-77D3-49BF-904E-3EC5FA162690Q38396256-93330012-AD0A-4C1E-ABE7-38B9B3F5369FQ38401281-B2AE84F6-D3A7-4F50-8942-1A3F087BA54BQ38635747-31CE1AC9-DA5E-42A1-A9E8-EE2DA414F5C1Q38656364-DE57FFDE-FF17-4823-A79A-5E65E758DE4EQ38672923-4DBD3683-A94E-4BF4-848D-ACFD47BCBCADQ38682012-32A2EF04-5684-4B75-98E6-B3345362C5C4Q38765117-6F8DB26F-665B-4E1A-AF1D-15B7ECC545A5Q38817125-A042AE01-4197-424E-B31E-AF5F831F4CFBQ38869502-C8BF9F0F-5BE6-4DA6-8299-41245E726F9BQ38970275-A2AC5058-26F7-435E-8F87-B50564FD304FQ39147735-E0CDB719-F2BA-4109-B706-296687385583Q42367885-DD06D87D-C284-4564-B00D-67CD0119577AQ42380237-66FD254F-D0EE-4F4B-8748-37C9787F79B6Q47707224-92BAE000-FAA5-4533-88C7-9A326316EFEEQ47865745-B7625500-50A2-4A31-A25F-DDCA18D21A62Q48957870-A9467890-2D5D-498E-8ECA-7721EDA5CF63Q50044401-DB5694D2-A8A7-4AD6-9DC2-25E46A391602Q50096700-D288577B-475B-4E5B-985C-D257CC343588Q50864337-ABF7254E-A648-4470-8830-B967329F0A77Q52593402-F4EF3997-E914-4E21-993E-B236874E3EC0Q55560602-5B3D3BBC-E3A6-4640-8E89-25B53CBB16E5Q56384060-CF9CF5F4-CF33-4F24-BDFA-83A1B6CB3EA4Q57143053-156FCE4E-3E0B-41A6-AD38-29CBE35DFD3B
P2860
Switching P2Y12-receptor inhibitors in patients with coronary artery disease.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Switching P2Y12-receptor inhibitors in patients with coronary artery disease.
@en
type
label
Switching P2Y12-receptor inhibitors in patients with coronary artery disease.
@en
prefLabel
Switching P2Y12-receptor inhibitors in patients with coronary artery disease.
@en
P2093
P2860
P1476
Switching P2Y12-receptor inhibitors in patients with coronary artery disease.
@en
P2093
Dominick J Angiolillo
Fabiana Rollini
Francesco Franchi
P2860
P2888
P356
10.1038/NRCARDIO.2015.113
P407
P577
2015-08-18T00:00:00Z
P6179
1000347427